Hamidreza Raeisi-Dehkordi, Mojgan Amiri, Sara Beigrezaei, Hugo G Quezada-Pinedo, Marinka Steur, Angeline Chatelan, Trudy Voortman, Oscar H Franco, Taulant Muka
{"title":"Response to Letter to Editor from Yeap et al: \"Endogenous sex steroid hormones, sex hormone-binding globulin, and risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies\".","authors":"Hamidreza Raeisi-Dehkordi, Mojgan Amiri, Sara Beigrezaei, Hugo G Quezada-Pinedo, Marinka Steur, Angeline Chatelan, Trudy Voortman, Oscar H Franco, Taulant Muka","doi":"10.1210/clinem/dgaf415","DOIUrl":"https://doi.org/10.1210/clinem/dgaf415","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bu B Yeap, Ross J Marriott, Leen Antonio, Leon Flicker, Gary A Wittert, Frederick C W Wu, Kevin Murray
{"title":"Letter to Editor from Yeap et al: \"Endogenous sex steroid hormones, sex hormone-binding globulin, and risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies\".","authors":"Bu B Yeap, Ross J Marriott, Leen Antonio, Leon Flicker, Gary A Wittert, Frederick C W Wu, Kevin Murray","doi":"10.1210/clinem/dgaf414","DOIUrl":"https://doi.org/10.1210/clinem/dgaf414","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Segarra-Balao, Juan de Dios Barranco-Ochoa, María de Damas-Medina, Beatriz Andrea Sánchez-Arquelladas, Eva Antonaya-Rubia, Carmen Rosa-Garrido, María Josefa Martínez-Ramírez, Alberto José Moreno-Carazo
{"title":"A PTH Value at 6 Hours Post-Surgery Predicts the Diagnosis of Transient and Permanent Hypoparathyroidism.","authors":"Ana Segarra-Balao, Juan de Dios Barranco-Ochoa, María de Damas-Medina, Beatriz Andrea Sánchez-Arquelladas, Eva Antonaya-Rubia, Carmen Rosa-Garrido, María Josefa Martínez-Ramírez, Alberto José Moreno-Carazo","doi":"10.1210/clinem/dgaf416","DOIUrl":"https://doi.org/10.1210/clinem/dgaf416","url":null,"abstract":"<p><strong>Context: </strong>Parathyroid hormone (PTH) levels after thyroid surgery are generally used to detect patients at risk of developing postoperative hypoparathyroidism. However, there is still a lack of consensus about the threshold value regarding its evaluation, the definition of gland function recovery and the classification of hypoparathyroidism as permanent.</p><p><strong>Objective: </strong>PTH levels (determined 6 hours after total thyroidectomy) could be effective for early prediction of the risk of post-surgical hypocalcemia and intravenous calcium requirements during hospitalization, comparing it with the predictive capacity of serum calcium levels at 24 and 48 hours after surgery. We also aim to study the efficacy of the measurement of PTH levels for the predictive diagnosis of permanent hypoparthyroidism.</p><p><strong>Design: </strong>Prospective cohort study between September 2021 and November 2023.</p><p><strong>Setting: </strong>A public tertiary care hospital (Jaén, Spain).</p><p><strong>Patients: </strong>We collected data on 105 patients undergoing total thyroidectomy.</p><p><strong>Main outcome measures: </strong>PTH levels were measured 6 hours postoperatively (PTH6h). Additionally, corrected calcium levels, adjusted for total protein, were measured at 24 hours (Ca24h) and 48 hours (Ca48h) post-surgery.</p><p><strong>Results: </strong>In our study, a PTH value at 6 hours post-surgery < 10.10 pg/ml, suggests, with high sensitivity and specificity, to be a very effective measure for identifying patients who would develop either transient (AUC=0.991, 95% CI 0.978-1) and permanent hypoparathyroidism (AUC=0.961, 95% CI 0.952-0.997).</p><p><strong>Conclusions: </strong>Measuring PTH levels at 6 hours post-thyroidectomy is an accurate method for predicting which patients are at risk of developing transient and/or permanent hypoparathyroidism.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: \"Temple Syndrome: Comprehensive Clinical Study in Genetically Confirmed 60 Japanese Patients\".","authors":"","doi":"10.1210/clinem/dgaf398","DOIUrl":"https://doi.org/10.1210/clinem/dgaf398","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin C Greenspun, Daniel Aryeh Metzger, Sally Lee, Bradley E Pearson, Jin H Li, Shuibing Chen, Rasa Zarnegar, Thomas J Fahey Iii, Brendan M Finnerty
{"title":"Long Term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.","authors":"Benjamin C Greenspun, Daniel Aryeh Metzger, Sally Lee, Bradley E Pearson, Jin H Li, Shuibing Chen, Rasa Zarnegar, Thomas J Fahey Iii, Brendan M Finnerty","doi":"10.1210/clinem/dgaf391","DOIUrl":"https://doi.org/10.1210/clinem/dgaf391","url":null,"abstract":"<p><strong>Context: </strong>Longer-term survival is possible for some patients with Anaplastic Thyroid Cancer (ATC). However, genomic factors associated with improved survival are poorly characterized.</p><p><strong>Objective: </strong>To develop a mathematical model to predict mutation-based survival risk in ATC.</p><p><strong>Design: </strong>Retrospective cohort study of 204 ATC samples from the cBioPortal database, divided into 80% training and 20% validation cohorts. Multivariate analysis identified prognostic genes, used to construct a point-based risk model. KEGG pathway enrichment and BRAF subanalyses were performed.</p><p><strong>Setting: </strong>Multi-institutional, international genomic database.</p><p><strong>Patients or other participants: </strong>Samples were included if sequencing and survival data were available (N=204).</p><p><strong>Intervention(s): </strong>Not applicable.</p><p><strong>Main outcome measure(s): </strong>The prespecified primary outcome was overall survival.</p><p><strong>Results: </strong>Fourteen genes were associated with increased risk - TET1, MAPK12, ATP10A, PIK3CA, MUC4, PNPLA2, PLD4, EGLN2, BSN, FLNC, RADIL, ZMYND8, FRAS1, RECQL4. More aggressive (n=37) and less aggressive cohorts (n=128) were determined using the maximally selected rank statistic, yielding a point threshold of 0.27. The predictive performance of the risk model demonstrated a C-index of 0.74. On Kaplan Meier analysis, 1-year survival differed for more aggressive patients (0%) compared to less aggressive patients (32%). For the validation cohort, survival remained significantly different between risk cohorts and on BRAF subanalysis. Each risk cohort subsequently underwent KEGG pathway enrichment analysis which showed significantly increased enrichment across several pathways for more aggressive tumors.</p><p><strong>Conclusions: </strong>This model identifies mutated genes that are associated with the most aggressive ATCs and thus may aid in preoperative risk assessment when evaluating patients for surgery for curative intent.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sami SeungMi Jin, Anushree Dugar, Andrew N Hoofnagle, Amber P Sanchez, David M Ward, Joachim H Ix, Charles Ginsberg
{"title":"Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23.","authors":"Sami SeungMi Jin, Anushree Dugar, Andrew N Hoofnagle, Amber P Sanchez, David M Ward, Joachim H Ix, Charles Ginsberg","doi":"10.1210/clinem/dgaf400","DOIUrl":"https://doi.org/10.1210/clinem/dgaf400","url":null,"abstract":"<p><strong>Context: </strong>Therapeutic plasma exchange (TPE) removes plasma proteins and other unwanted substances, causing non-specific alterations of plasma components. A previous study showed ∼70% reduction in vitamin D metabolites following a single TPE treatment, prompting further investigation into TPE's effects on vitamin D regulators and metabolites: calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23).</p><p><strong>Objective: </strong>This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in persons undergoing TPE.</p><p><strong>Methods: </strong>Measurements were taken immediately before, immediately after, and at follow-up. Paired t-tests compared the percent changes in metabolites from pre- to post-TPE.</p><p><strong>Results: </strong>Study participants (N=42) had a mean age of 55 ± 16 years, 28 (67%) were female and 32 (76%) were white. TPE led to acute changes in calcium [-9%, (95% CI -11%, -8%)], phosphate [-14%, (-18%, -11%)], and FGF-23 [-12%, (-18%, -6%)] concentrations. In contrast, PTH levels increased [91% (63%, 119%)] from baseline to post-TPE. While most metabolites returned to baseline by the follow-up visit (median 4 [IQR 3,7] days), nearly 25% of patients experienced persistent asymptomatic hypocalcemia. This persistent calcium deficit was not fully corrected by continuous IV calcium gluconate infusions administered during the study, nor by the endogenously increased PTH levels.</p><p><strong>Conclusions: </strong>These findings underscore the need for improved care protocols and vigilant monitoring of mineral metabolism TPE patients, especially those receiving long-term treatment. Further research is warranted to understand the enduring effects of TPE on mineral metabolism and develop strategies to prevent complications.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neal Pohlman, Prem N Patel, Utibe R Essien, Jasmyn J Tang, Joshua J Joseph
{"title":"Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.","authors":"Neal Pohlman, Prem N Patel, Utibe R Essien, Jasmyn J Tang, Joshua J Joseph","doi":"10.1210/clinem/dgaf295","DOIUrl":"10.1210/clinem/dgaf295","url":null,"abstract":"<p><p>Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease, driving elevated morbidity and mortality. CKM syndrome encompasses a continuum of interrelated metabolic, renal, and cardiovascular dysfunctions attributed to obesity, impaired glucose regulation, and chronic inflammation. This review synthesizes recent literature on the efficacy of cardiorenal protective medications including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in CKM syndrome management. Sodium-glucose cotransporter 2 inhibitor agents show promising outcomes, including reduced cardiovascular mortality, hospitalization for heart failure, and adverse kidney events across diverse patient populations, regardless of type 2 diabetes mellitus status. Similarly, glucagon-like peptide-1 receptor agonist agents demonstrate substantial benefits in weight loss, glycemic control, and reduced cardiovascular and kidney events. The review also highlights the necessity of equitable pharmacotherapy distribution to ensure that high-risk populations benefit from these advancements and the need for further precision-based therapeutic frameworks, policy innovations, and tailored interventions focused on CKM syndrome management. Finally, we discuss strategies for translating these findings into practice through an equity-focused lens to advance CKM health.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"2105-2122"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editor From Yang et al: \"Cognitive Risk Stratification Score in Middle-Aged and Older Adults With Type 2 Diabetes: A Cross-Sectional Study\".","authors":"Xinyue Yang, Xiaoying Zhao, Yu Jiang","doi":"10.1210/clinem/dgaf307","DOIUrl":"10.1210/clinem/dgaf307","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"e2804-e2805"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: \"Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline\".","authors":"","doi":"10.1210/clinem/dgaf310","DOIUrl":"10.1210/clinem/dgaf310","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"e2810"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Miriam Larouche, Jean Bergeron, Diane Brisson, Nathalie Laflamme, Noémie Audet-Verreault, Claire Sharon, Sybil Charrière, Melanie Rama, Delphine Collin-Chavagnac, Philippe Moulin, Daniel Gaudet
{"title":"Course of Pregnancies and Occurrence of Acute Pancreatitis in Women with Chylomicronemia.","authors":"Miriam Larouche, Jean Bergeron, Diane Brisson, Nathalie Laflamme, Noémie Audet-Verreault, Claire Sharon, Sybil Charrière, Melanie Rama, Delphine Collin-Chavagnac, Philippe Moulin, Daniel Gaudet","doi":"10.1210/clinem/dgaf409","DOIUrl":"https://doi.org/10.1210/clinem/dgaf409","url":null,"abstract":"<p><strong>Objective: </strong>Chylomicronemia is characterized by extreme hypertriglyceridemia (triglycerides values >10 mmol/L). It may be caused by bi-allelic combination of pathogenic variant (familial chylomicronemia syndrome (FCS)) or by genetic susceptibility combined with comorbidities and environmental factors (multifactorial chylomicronemia syndrome (MCS)). Acute pancreatitis (AP) is the most serious complication of CM. In the general population, the prevalence of AP during pregnancy is estimated to be <0.35%. As triglycerides levels significantly increase during pregnancy, it may affect the course of pregnancy and further increase the risk of AP in women with chylomicronemia.</p><p><strong>Methods: </strong>116 pregnancies involving 49 European and North American women with history of chylomicronemia (20 FCS, 29 MCS) were retrospectively reviewed. The occurrence of AP, the course of pregnancy, fetal development and delivery were evaluated.</p><p><strong>Results: </strong>42% of FCS and 10% of MCS women experienced at least one AP episode during pregnancy (p=0.01). Compared to MCS, women with FCS presented a higher percentage of pregnancies with AP (17% vs 5%, p=0.02). Among all reviewed pregnancy-related AP, 56% occurred in primigravida FCS women compared to 0% in MCS. Premature deliveries were elevated in both groups although more frequent in FCS (56%) vs MCS (19%) (p=0.01). The percentage of miscarriages (11.8% vs 10.7%) and fetal failure to thrive (5.9% vs 9.2%) were not significantly different between the two cohorts.</p><p><strong>Conclusions: </strong>In this study, pregnant women with chylomicronemia had 30-fold (MCS) to 120-fold (FCS) higher occurrence of AP compared to the general population. Chylomicronemia per se does not seem to influence fetal development.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}